Metraipolis › archive › dc_83db899d1c13
Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid — Europe PMC PMID:41117364
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41117364
- DOI
- 10.1177/11206721251388170
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T04:33:11.758Z
- SHA-256 of the archived text
0917f7c5beb6432d6b8f1eaabb8c6764040f08f52a72eb47926898dd46f86b2f- Stable URL of this page
https://metraipolis.com/documento/dc_83db899d1c13
How to cite
Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid — Europe PMC PMID:41117364 — Europe PMC (en), https://europepmc.org/article/MED/41117364 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_83db899d1c13 (Metraipolis archive dc_83db899d1c13, sha256 0917f7c5beb6432d6b8f1eaabb8c6764040f08f52a72eb47926898dd46f86b2f)
BibTeX
@misc{dc83db899d1c13,
title = {Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid — Europe PMC PMID:41117364},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41117364},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_83db899d1c13; sha256 0917f7c5beb6432d6b8f1eaabb8c6764040f08f52a72eb47926898dd46f86b2f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41117364. Agents can read the archived copy with the MCP tool read_document.